ITF Therapeutics LLC Announces U.S. Commercial Availability of DUVYZAT™ (givinostat) for Treatment of Patients With Duchenne Muscular Dystrophy 

 First nonsteroidal treatment approved for patients six years of age and older with DMD regardless of genetic mutation now available in the U.S. 

ITF also announces the launch of ITF ARC (Access, Resources and Care) patient services program to bring suite of support and educational resources to patients and their families 

Read the Full Press Release HERE